<DOC>
	<DOCNO>NCT01177722</DOCNO>
	<brief_summary>The purpose study generate immunogenicity safety data investigational hexavalent DTaP-IPV-Hep B-PRP-T vaccine compare control vaccine , Infanrix hexa™ give along Prevenar™ Rotarix™ vaccine . Primary Objectives : - To demonstrate equivalence immunogenicity 3 lots DTaP-IPV-Hep B-PRP-T vaccine 1 month 3-dose primary series ( 2 , 4 6 month ) give Prevenar™ Rotarix™ , term immunoresponses . - To demonstrate non-inferiority hexavalent DTaP-IPV-Hep B-PRP-T vaccine license hexavalent Infanrix hexa vaccine give Prevenar™ Rotarix™ . Secondary Objectives : - To describe group immunogenicity parameter antigens vaccine - To assess safety profile term solicit unsolicited adverse event serious adverse event group vaccine .</brief_summary>
	<brief_title>A Study DTaP-IPV-Hep B-PRP-T Vaccine Given With Prevenar™ Rotarix™ Healthy Latin American Infants</brief_title>
	<detailed_description>Each participant receive 3 dos 1 3 lot investigational hexavalent vaccine control vaccine , Infanrix hexa™ , administer Prevenar™ 2 , 4 , 6 month age Rotarix™ 2 4 month age . All participant monitor safety 6 month last injection primary vaccination series .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Tetanus</mesh_term>
	<mesh_term>Diphtheria</mesh_term>
	<mesh_term>Poliomyelitis</mesh_term>
	<mesh_term>Whooping Cough</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
	<criteria>Inclusion Criteria : Two month old infant ( 55 65 day old ) day inclusion . Born full term pregnancy ( ≥ 37 week ) birth weight ≥ 2.5 kg . Informed consent form sign one parent legally acceptable representative per local requirement . Able attend schedule visit comply trial procedure . Received Hepatitis B Bacille de CalmetteGuérin ( BCG ) vaccine birth one month life agreement national immunization calendar . Exclusion Criteria : Participation another clinical trial 4 week precede first trial vaccination . Planned participation another clinical trial present trial period . Known suspect congenital acquire immunodeficiency , immunosuppressive therapy , longterm systemic corticosteroid therapy . Known systemic hypersensitivity vaccine component history lifethreatening reaction trial vaccine vaccine contain substance . Chronic illness stage could interfere trial conduct completion , opinion Investigator . Blood bloodderived product receive since birth might interfere assessment immune response . Any vaccination trial vaccination ( except Hepatitis B Bacille de Calmette Guérin give birth ) . Any planned vaccination 1 month last trial vaccination ( except study vaccine , rotavirus pneumococcal conjugate vaccine ) . Documented history pertussis , tetanus , diphtheria , poliomyelitis , Haemophilus influenzae type b Hepatitis B infection ( ) ( confirm either clinically , serologically microbiologically ) . Previous vaccination pertussis , tetanus , diphtheria , poliomyelitis , Haemophilus influenzae type b infection . Known personal maternal history Human Immunodeficiency Virus ( HIV ) , hepatitis B surface antigen ( HBsAg ) hepatitis C seropositivity . Known coagulopathy , thrombocytopenia bleed disorder precede inclusion contraindicate intramuscular ( IM ) vaccination . History seizures encephalopathy . Febrile illness ( temperature ≥ 38.0°C ) , moderate severe acute illness/infection day inclusion , accord Investigator judgment .</criteria>
	<gender>All</gender>
	<minimum_age>55 Days</minimum_age>
	<maximum_age>65 Days</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>Diphtheria</keyword>
	<keyword>Tetanus</keyword>
	<keyword>Whooping cough</keyword>
	<keyword>Hepatitis B</keyword>
	<keyword>Poliomyelitis</keyword>
	<keyword>Diphtheria-Tetanus-acellular Pertussis Vaccines</keyword>
</DOC>